文献速递神经重症脑血管病外科

血小板单采与补液治疗神经外科ICU继发性血小板增多症疗效比较

Comparative Efficacy of Plateletpheresis and Rehydration for Managing Secondary Thrombocytosis in the Neurosurgical Intensive Care Unit.
PubMed 文献 · World Neurosurg · 2025-08-20

本研究回顾性纳入2020年4月至2024年7月皖南医学院第一附属医院神经外科ICU的68例继发性血小板增多症患者,比较血小板单采(n=31)与补液(n=37)的疗效。血小板单采在降低血小板计数(64% vs. 55%,P<0.001)和血小板压积(65% vs. 55%,P<0.001)方面优于补液,且治疗周期更少、NSICU及总住院时间更短、住院费用更低;3个月功能结局两组相当。

要点

  • 血小板单采降低血小板计数和血小板压积的幅度显著优于补液。
  • 血小板单采组治疗周期更少、NSICU及总住院时间更短、住院费用更低。
  • 两组3个月改良Rankin量表评分相当,功能结局无显著差异。

核心结论

  • 对于神经重症继发性血小板增多症患者,血小板单采可能是快速降低血小板的优选治疗方式,具有靶向细胞减灭、安全性良好和资源效率更优的特点。

研究设计与样本

  • 回顾性队列研究,纳入2020年4月至2024年7月皖南医学院第一附属医院神经外科ICU的68例继发性血小板增多症患者,分为血小板单采组(n=31)和补液组(n=37)。

主要发现

  • 血小板单采组血小板计数降幅为64%,补液组为55%(P<0.001)。
  • 血小板单采组血小板压积降幅为65%,补液组为55%(P<0.001)。
  • 补液组中性粒细胞降幅为55%、单核细胞降幅为50%,血小板单采组分别为25%和17%(P<0.001)。
  • 血小板单采组治疗周期更少、NSICU及总住院时间更短、住院费用更低。
  • 两组3个月改良Rankin量表评分相当。

临床怎么用

  • 神经重症继发性血小板增多症需快速降低血小板时,可优先考虑血小板单采。

局限性

  • 本文为单中心回顾性队列研究,样本量68例,结论需多中心随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secondary thrombocytosis (ST) is associated with increased thromboembolic risk in neurocritical care settings; however, its optimal management remains a subject of debate. We aimed to compare the therapeutic efficacy and clinical outcomes of plateletpheresis versus rehydration therapy in patients with ST. METHODS: A retrospective cohort study was conducted in the neurosurgical intensive care unit (NSICU) of the First Affiliated Hospital of Wannan Medical College from April 2020 to July 2024. A total of 68 patients with ST were enrolled and allocated to the plateletpheresis group (n = 31) or the rehydration group (n = 37). The primary endpoints were changes in complete blood count parameters. Secondary outcomes included NSICU and total hospital length of stay, hospitalization costs, and 3-month modified Rankin Scale scores. RESULTS: Both interventions demonstrated significant efficacy in managing ST. Plateletpheresis yielded superior cytoreductive effects, with greater reductions in platelet count (64% vs. 55%; P < 0.001) and plateletcrit (65% vs. 55%; P < 0.001) compared to rehydration. In contrast, rehydration produced nonspecific hematological effects, notably a significant decrease in leukocyte subpopulations-neutrophils (55% vs. 25%) and monocytes (50% vs. 17%) (P < 0.001). Clinically, plateletpheresis was associated with lower treatment cycles, shorter NSICU and hospital stays, as well as reduced hospitalization costs. Functional outcomes at 3 months were comparable between the groups. CONCLUSIONS: Plateletpheresis appears to be the preferred therapeutic approach for rapid platelet reduction in neurocritical patients with ST, offering targeted cytoreduction, a favorable safety profile, and improved resource efficiency. Further validation through multicenter randomized controlled trials is warranted.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yu Z, Tao Y, Zhu M, et al. Comparative Efficacy of Plateletpheresis and Rehydration for Managing Secondary Thrombocytosis in the Neurosurgical Intensive Care Unit. World Neurosurg. 2025. PMID: 40845945. doi:10.1016/j.wneu.2025.124380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。